Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial-Reference-Cited by-同舟云学术

Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial

Published:2019-05 Issue:5 Volume:7 Page:387-401
ISSN:2213-2600
Container-title:The Lancet Respiratory Medicine
language:en
Short-container-title:The Lancet Respiratory Medicine

Author:

Reck Martin,Mok Tony S K,Nishio Makoto,Jotte Robert M,Cappuzzo Federico,Orlandi Francisco,Stroyakovskiy Daniil,Nogami Naoyuki,Rodríguez-Abreu Delvys,Moro-Sibilot Denis,Thomas Christian A,Barlesi Fabrice,Finley Gene,Lee Anthony,Coleman Shelley,Deng Yu,Kowanetz Marcin,Shankar Geetha,Lin Wei,Socinski Mark A,Reck Martin,Mok Tony SK,Nishio Makoto,Jotte Robert M,Cappuzzo Federico,Orlandi Francisco,Stroyakovskiy Daniil,Nogami Naoyuki,Rodríguez-Abreu Delvys,Moro-Sibilot Denis,Thomas Christian A,Barlesi Fabrice,Finley Gene,Lee Anthony,Coleman Shelley,Deng Yu,Kowanetz Marcin,Shankar Geetha,Lin Wei,Socinski Mark A

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine

Reference39 articles.

1. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer;Sandler;N Engl J Med,2006

2. Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer;Gandhi;N Engl J Med,2018

3. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Planchard;Ann Oncol,2018

4. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer;Reck;N Engl J Med,2016

5. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer;Soria;N Engl J Med,2018

Cited by 752 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in clinical trials on perioperative immune checkpoint inhibitors for resectable non-small cell lung cancer: A comprehensive review;International Immunopharmacology;2024-11

2. Tumor immune microenvironment of NSCLC with EGFR exon 20 insertions may predict efficacy of first-line ICI-combined regimen;Lung Cancer;2024-09

3. Chemotherapy and programmed cell death protein 1/programmed death-ligand 1 inhibitor combinations for tyrosine kinase inhibitor-resistant, epidermal growth factor receptor-mutated non-small-cell lung cancer: a meta-analysis;ESMO Open;2024-09

4. Real world results of locally advanced and metastatic lung cancer patients treated with platinum doublet chemotherapy in first line: Moroccan cohort;Translational Oncology;2024-09

5. Suggestions for the predictive factors related to irAES and research methods during dose switching of pembrolizumab treatment in patients with advanced NSCLC;Journal of Thoracic Oncology;2024-09